912 related articles for article (PubMed ID: 12559794)
1. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
[TBL] [Abstract][Full Text] [Related]
2. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine.
Isaka M; Komiya T; Takahashi M; Yasuda Y; Taniguchi T; Zhao Y; Matano K; Matsui H; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2004 Aug; 22(23-24):3061-8. PubMed ID: 15297056
[TBL] [Abstract][Full Text] [Related]
3. Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit.
Isaka M; Yasuda Y; Kozuka S; Miura Y; Taniguchi T; Matano K; Goto N; Tochikubo K
Vaccine; 1998 Oct; 16(17):1620-6. PubMed ID: 9713937
[TBL] [Abstract][Full Text] [Related]
4. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant.
Isaka M; Yasuda Y; Kozuka S; Taniguchi T; Matano K; Maeyama J; Komiya T; Ohkuma K; Goto N; Tochikubo K
Vaccine; 1999 Nov; 18(7-8):743-51. PubMed ID: 10547435
[TBL] [Abstract][Full Text] [Related]
5. A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers.
Berstad AKH; Holst J; Frøholm LO; Haugen IL; Wedege E; Oftung F; Haneberg B
J Med Microbiol; 2000 Feb; 49(2):157-163. PubMed ID: 10670566
[TBL] [Abstract][Full Text] [Related]
6. Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant.
Isaka M; Yasuda Y; Mizokami M; Kozuka S; Taniguchi T; Matano K; Maeyama J; Mizuno K; Morokuma K; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2001 Jan; 19(11-12):1460-6. PubMed ID: 11163669
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice.
Jabbal-Gill I; Fisher AN; Rappuoli R; Davis SS; Illum L
Vaccine; 1998 Dec; 16(20):2039-46. PubMed ID: 9796062
[TBL] [Abstract][Full Text] [Related]
8. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies.
Yasuda Y; Isaka M; Taniguchi T; Zhao Y; Matano K; Matsui H; Morokuma K; Maeyama J; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2003 Jun; 21(21-22):2954-63. PubMed ID: 12798639
[TBL] [Abstract][Full Text] [Related]
9. Genital antibody responses in mice after intranasal infection with an attenuated candidate vector strain of Bordetella pertussis.
Mielcarek N; Nordström I; Menozzi FD; Locht C; Holmgren J
Infect Immun; 2000 Feb; 68(2):485-91. PubMed ID: 10639408
[TBL] [Abstract][Full Text] [Related]
10. Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies.
Polewicz M; Gracia A; Garlapati S; van Kessel J; Strom S; Halperin SA; Hancock RE; Potter AA; Babiuk LA; Gerdts V
Vaccine; 2013 Jun; 31(31):3148-55. PubMed ID: 23684829
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
[TBL] [Abstract][Full Text] [Related]
12. Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine.
Berstad AK; Oftung F; Korsvold GE; Haugen IL; Froholm LO; Holst J; Haneberg B
Vaccine; 2000 May; 18(22):2323-30. PubMed ID: 10738087
[TBL] [Abstract][Full Text] [Related]
13. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
[TBL] [Abstract][Full Text] [Related]
14. Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Infect Immun; 2000 Oct; 68(10):5749-55. PubMed ID: 10992481
[TBL] [Abstract][Full Text] [Related]
15. Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment.
Cropley I; Douce G; Roberts M; Chatfield S; Pizza M; Marsili I; Rappuoli R; Dougan G
Vaccine; 1995 Dec; 13(17):1643-8. PubMed ID: 8719514
[TBL] [Abstract][Full Text] [Related]
16. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
17. Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis.
Renauld-Mongénie G; Mielcarek N; Cornette J; Schacht AM; Capron A; Riveau G; Locht C
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7944-9. PubMed ID: 8755582
[TBL] [Abstract][Full Text] [Related]
18. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
[TBL] [Abstract][Full Text] [Related]
20. Induction of immune responses and prevention of alveolar bone loss by intranasal administration of mice with Porphyromonas gingivalis fimbriae and recombinant cholera toxin B subunit.
Takahashi Y; Kumada H; Hamada N; Haishima Y; Ozono S; Isaka M; Yasuda Y; Tochikubo K; Umemoto T
Oral Microbiol Immunol; 2007 Dec; 22(6):374-80. PubMed ID: 17949339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
